You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: TRANSGENOMIC, INC. Topic: 103
DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PROTHERA BIOLOGICS, LLC Topic: NIAID
DESCRIPTION (provided by applicant): Anthrax is recognized as a class A bio-threat microbial pathogen that is readily weaponized and exceedingly difficult to treat. This bacterium is highly virulent inducing lethal infection in immunologically normal hosts by its intrinsic capacity to disseminate rapidly and induce sepsis, along with its ability to generate two highly potent exotoxins, lethal toxi ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health